Obtaining polymeric nanoparticles of Eudragit® S100 for pH-dependent release of olanzapine.
Schizophrenia; Olanzapine; Eudragit®; pH-responsive system
Schizophrenia is the most common psychotic disorder in the world. Olanzapine is a second-generation antipsychotic that is highly effective in treatment. However, the administration of this medication can cause side effects, such as muscle rigidity, pyrexia, drowsiness, tremor, spasms, excessive sweating, confusion, tachycardia, personality changes, and hallucinations. Therefore, it is necessary to seek new drug delivery systems for this medication to minimize undesirable adverse effects, increase its bioavailability, and consequently improve its therapeutic efficacy. This study investigated the development of pH-responsive systems for olanzapine using Eudragit® S100 as a carrier. The material obtained was characterized using techniques such as Fourier Transform Infrared Spectroscopy, X-ray Diffraction, X-ray Fluorescence, Thermogravimetry/Derivative Thermogravimetry, Differential Scanning Calorimetry, Dynamic Light Scattering, Scanning Electron Microscopy, and Energy Dispersive Spectroscopy. Through in vitro release studies, drug release was tested in gastric and intestinal media (pH 1.2 and pH 6.8), where it was possible to observe that the modified system was efficient in the controlled release of the drug olanzapine, gradually releasing approximately 49.7% of the drug over 4 hours.